Basic information Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Biochemical Reagents Agonist Inhibitors ML264

1/1

ML264 NEW

$30.00 1mg

$64.00 5mg

$97.00 10mg

Min. Order
Purity99.33%
Cas No1550008-55-3
Supply Ability10g
Update time2026-03-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	ML264
CAS No	1550008-55-3
EC-No
Min. Order
Purity	99.33%
Supply Ability	10g
Release date	2026/03/13

Product Introduction

Bioactivity

Name	ML264
Description	ML264 (CID-51003603) is a selective kruppel-like factor 5 (KLF5) inhibitor, which potently Inhibits growth of Colorectal Cancer.
Cell Research	For cell proliferation experiments, DLD-1 and HCT116 cells are treated with 10μM ML264 or with vehicle (DMSO). Live cells are collected at 24, 48 and 72 hours post treatment and their numbers are determined by counting using a Coulter counter; In MTS assay, DLD-1 and HCT116 cells are treated with 10μM ML264 or with vehicle (DMSO). After 24, 48, and 72 hours of incubations, 20 μL of MTS solution is added to each well and an analysis is performed according to the manufacturer's protocol. (Only for Reference)
In vitro	ML264 potently halts DLD-1 viability (IC50 = 29 nM) with high maximal effect (>90%). DLD-1 cells are human colorectal adenocarcinoma cells. ML264 has significant effects at submicromolar doses on other cell types as well, including HCT116 (human colorectal carcinoma), HT29 (human colorectal adenocarcinoma), and SW620 (human colorectal adenocarcinoma). The IEC-6 anti-target (a nontransformed rat intestinal epithelial cell line) is largely unaffected, with inhibition below 50% at the highest dose[1].This compound potently inhibits proliferation of CRC cells in vitro through modifications of the cell cycle profile[2].
In vivo	In an established xenograft mouse model of colon cancer, ML264 efficiently inhibits growth of the tumor within five days of treatment. this effect is caused by a significant reduction in proliferation and that ML264 potently inhibits the expression of KLF5 and EGR1, a transcriptional activator of KLF5[2].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 100 mg/mL (259.82 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+90% Corn Oil : 3.3 mg/mL (8.57 mM), Sonication is recommended.
Keywords	RNASynthesis \| RNA Synthesis \| ML-264 \| ML264 \| ML 264 \| Krüppel-like factor \| KLF5 \| KLF \| Inhibitor \| inhibit \| DNASynthesis \| DNA Synthesis \| CID51003603 \| CID 51003603
Inhibitors Related	5-Fluorouracil \| Adenine hemisulfate \| Guanidine hydrochloride \| Hexane-1,6-diol \| Methotrexate disodium \| 1,4-Naphthoquinone \| Adenine \| Vidarabine \| Carbazole \| Thymidine \| Docosanoic acid \| Usnic Acid
Related Compound Libraries	Bioactive Compound Library \| Pain-Related Compound Library \| Inhibitor Library \| NO PAINS Compound Library \| Stem Cell Differentiation Compound Library \| Anti-Prostate Cancer Compound Library \| Anti-Aging Compound Library \| Immunology/Inflammation Compound Library \| Bioactive Compounds Library Max \| Covalent Inhibitor Library \| Anti-Cancer Compound Library \| Anti-Cancer Active Compound Library

show more

Company Profile Introduction

Citations

You may like

Recommended supplier

Send Inquriy